Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Howarth

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
The Health Service Journal|September 7, 2012
Beyond the tickboxSeraphim J Rose Patel, David Walton, Paul Howarth
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2025
Datopotamab Deruxtecan in Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 StudyJacob Sands, Myung-Ju Ahn, Aaron Lisberg, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 14, 2025
A pooled analysis of datopotamab deruxtecan in patients with EGFR-mutated NSCLCMyung-Ju Ahn, Aaron Lisberg, Yasushi Goto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 9, 2024
Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 StudyMyung-Ju Ahn, Kentaro Tanaka, Luis Paz-Ares, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
The Health Service Journal|September 7, 2012
Beyond the tickboxSeraphim J Rose Patel, David Walton, Paul Howarth
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2025
Datopotamab Deruxtecan in Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 StudyJacob Sands, Myung-Ju Ahn, Aaron Lisberg, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 14, 2025
A pooled analysis of datopotamab deruxtecan in patients with EGFR-mutated NSCLCMyung-Ju Ahn, Aaron Lisberg, Yasushi Goto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 9, 2024
Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 StudyMyung-Ju Ahn, Kentaro Tanaka, Luis Paz-Ares, et al.
Pageof 1